Noah M. Leibowitz is a Partner in the Firm’s Intellectual Property Group and Litigation Department. He has litigated patent cases in courts across the country and has experience in all aspects of such cases, including discovery, Markman hearings, dispositive motion practice, and pre–trial, trial and appeal to the Federal Circuit. He has litigated cases involving a variety of complex technologies, including semiconductor manufacturing and fabrication, computer hardware and software, videoconferencing and data conferencing systems and methods, pharmaceuticals, medical devices, global positioning systems, and consumer products for clients such as Intel, Cisco, 3Com, Verizon, Verizon Wireless, Daiichi Sankyo, Q–Med, CSR, Avistar Communications, JDS Uniphase, Personal Chemistry, The Nielsen Company and others.
Noah has particular familiarity with the pharmaceutical, healthcare and biotechnology industries and experience in Hatch–Waxman patent litigation. Since 2003, Noah has represented Daiichi Sankyo (formerly Daiichi Pharmaceutical) in ongoing litigation to enforce Daiichi’s patent on its multibillion–dollar–per–year blockbuster anti–infective Levaquin®. He was a member of the trial team that successfully defended the Levaquin® patent in an eight–week trial and on appeal. In addition, Noah successfully represented Daiichi Sankyo in Hatch-Waxman challenges to its multimillion–dollar–per–year Benicar® and Benicar® HCT products in a case tried over three weeks.
Noah represented Biosynexus, Inc., in a licensing dispute against Glaxo Group (a division of GlaxoSmithKline) and MedImmune, related to the development of a monoclonal antibody therapy for the prevention of staphylococcal infections in premature babies. Noah successfully obtained a preliminary injunction on behalf of Biosynexus and defended that decision on appeal. Noah also represented Q–Med in a Section 337 patent investigation in the U.S. International Trade Commission related to Q–Med’s Restylane® product.
Noah’s transactional practice includes negotiating complex collaboration, development and license agreements in the biotechnology, healthcare and pharmaceutical industries. Noah also negotiates agreements, conducts intellectual property diligence, and advises on merger and acquisition transactions and securities offerings. He has participated in over 100 consummated or contemplated transactions and offerings, many involving companies in the healthcare and pharmaceutical industries, including Abbott Laboratories, Accellent, Atricure, Cardinal Health, CSL Limited, Galen Holdings, Indevus Pharmaceuticals, Link Spine Group, Perseus Soros BioFund/Aisling Capital and Stiefel Laboratories.
Noah received his A.B., magna cum laude, in Biology and Psychology from Columbia University in 1996 and his J.D. from Columbia Law School (James Kent Scholar, Harlan Fiske Stone Scholar) in 1999. While in school, he conducted independent research in a biochemistry laboratory, leading to publication in a peer-reviewed journal.